November 9-11, 2020 | Virtual Conference


Howard Chazin, M.D., MBA

Director, Clinical Safety Surveillance Staff (CSSS), IO, OGD, CDER

Howard Chazin, MD, MBA is the Director of the Clinical Safety Surveillance Staff in CDER’s Office of Generic Drugs. He leads a multidisciplinary team of pharmacists, physicians and data analysts tasked with identifying and assessing emerging complex generic drug safety issues. From 2011-2016, Dr. Chazin was the Deputy Director and Acting Director of the Division of Hematology Clinical Review in the Office of Blood Research and Review in the Center for Biologic Evaluation and Research. From 2002 through 2011, he filled several roles in CDER’s Office of New Drugs (OND) Division of Neurology Products and the OND Guidance and Policy Team. He received his medical degree from the Rutgers-Robert Wood Johnson Medical School, completed a Neurology residency at the George Washington University Medical Center, and his MBA from the Carey Business School at Johns Hopkins University.

Skip to content